Showing results (491-500 of 538) with videos related to
Sort By:
Pageof 54
Breast Cancer (Tokyo, Japan)|June 13, 2024
Neoadjuvant talazoparib in patients with germline BRCA1/2 mutation-positive, early-stage triple-negative breast cancer: exploration of tumor BRCA mutational statusMelinda L Telli, Jennifer K Litton, J Thaddeus Beck, et al.Bioorganic & Medicinal Chemistry Letters|October 10, 2001
Discovery of heterocyclic ureas as a new class of raf kinase inhibitors: identification of a second generation lead by a combinatorial chemistry approachR A Smith, J Barbosa, C L Blum, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 21, 2018
Quality of life with talazoparib versus physician's choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trialJ Ettl, R G W Quek, K-H Lee, et al.Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|March 20, 2024
ECFS standards of care on CFTR-related disorders: Identification and care of the disordersN J Simmonds, K W Southern, E De Wachter, et al.The New England Journal of Medicine|August 16, 2018
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA MutationJennifer K Litton, Hope S Rugo, Johannes Ettl, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 19, 2010
Phase III multicenter trial of doxorubicin plus cyclophosphamide followed by paclitaxel compared with doxorubicin plus paclitaxel followed by weekly paclitaxel as adjuvant therapy for women with high-risk breast cancerDavid Loesch, F Anthony Greco, Neil N Senzer, et al.Breast Cancer Research and Treatment|March 22, 2017
A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancerJosé Baselga, Serafin M Morales, Ahmad Awada, et al.The British Journal of Dermatology|November 13, 2018
Dermatological manifestations in Noonan syndrome: a prospective multicentric study of 129 patients positive for mutationD Bessis, J Miquel, E Bourrat, et al.Science Translational Medicine|February 4, 2011
Readily available tissue-engineered vascular graftsShannon L M Dahl, Alan P Kypson, Jeffrey H Lawson, et al.The Journal of Clinical Investigation|September 4, 2013
Human antibodies that neutralize respiratory droplet transmissible H5N1 influenza virusesNatalie J Thornburg, David P Nannemann, David L Blum, et al.Pageof 54